National Institute of General Medical Sciences; Notice of Closed Meetings, 43860-43861 [2024-10989]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
43860
Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Notices
2017, entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–CA–04];
5. Chinese Patent Application No.
201780059356.4 effective filing date of
July 31, 2017, entitled ‘‘Anti-KRAS
G12D T Cell Receptors’’ [HHS Reference
No. E–175–2016–0–CN–05];
6. European Patent No. 3494133
issued July 6, 2022, entitled ‘‘AntiKRAS G12D T Cell Receptors’’ [HHS
Reference No. E–175–2016–0–EP–06];
a. Validated in the following
jurisdictions: AL, AT, BE, BG, CH, CY,
CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
HR, IE, IS, IT, LT, LU, LV, MC, MK, MT,
NL, NO, PL, PT, RO, RS, SE, SI, SK, SM
and TR.
7. Japanese Patent Application No.
2019–505220 effective filing date of July
31, 2017, entitled ‘‘Anti-KRAS G12D T
Cell Receptors’’ [HHS Reference No. E–
175–2016–0–JP–07];
8. United States Patent No. 10,611,816
issued April 7, 2020, entitled ‘‘AntiKRAS G12D T Cell Receptors’’ [HHS
Reference No. E–175–2016–0–US–08];
9. Israeli Patent No. 264425 issued
August 2, 2023, entitled ‘‘Anti-KRAS
G12D T Cell Receptors’’ [HHS Reference
No. E–175–2016–0–IL–09];
10. South Korean Patent No. 10–
2527052 issued April 25, 2023, entitled
‘‘Anti-KRAS G12D T Cell Receptors’’
[HHS Reference No. E–175–2016–0–KR–
10];
11. Singapore Patent Application No.
11201900654Q effective filing date of
July 31, 2017, entitled ‘‘Anti-KRAS
G12D T Cell Receptors’’ [HHS Reference
No. E–175–2016–0–SG–11];
12. Hong Kong Patent No.
HK40009637 issued July 7, 2023,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–HK–12];
13. Hong Kong Patent Application No.
19132196.7 effective filing date of July
31, 2017, entitled ‘‘Anti-KRAS G12D T
Cell Receptors’’ [HHS Reference No. E–
175–2016–0–HK–13];
14. Singapore Patent Application No.
10201913959W filed December 31,
2019, entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–SG–14];
15. United States Patent No.
11,208,456 issued December 28, 2021,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–US–15];
16. United States Patent No.
11,897,933 issued February 13, 2024,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–US–16];
17. United States Patent No.
11,840,561 issued December 12, 2023,
entitled ‘‘Anti-KRAS G12D T Cell
VerDate Sep<11>2014
19:14 May 17, 2024
Jkt 262001
Receptors’’ [HHS Reference No. E–175–
2016–0–US–17];
18. Japanese Patent No. 7413338
issued January 4, 2024, entitled ‘‘AntiKRAS G12D T Cell Receptors’’ [HHS
Reference No. E–175–2016–0–JP–18];
19. European Patent Application No.
22182473.3 filed July 1, 2022, entitled
‘‘Anti-KRAS G12D T Cell Receptors’’
[HHS Reference No. E–175–2016–0–EP–
19];
20. Israeli Patent Application No.
301894 filed April 3, 2023, entitled
‘‘Anti-KRAS G12D T Cell Receptors’’
[HHS Reference No. E–175–2016–0–IL–
01];
21. Hong Kong Patent Application No.
42023078137.9 filed August 28, 2023,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–HK–01];
22. Australian Patent Application No.
2023233125 filed September 21, 2023,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–AU–01];
23. Japanese Patent Application No.
2023–221526 filed December 27, 2023,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–JP–01];
24. United States Patent Application
No. 18/423,020 filed January 25, 2024,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–US–02]; and
25. Chinese Patent Application No.
202410214235.4 filed February 27,
2024, entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–CN–01].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to the
following:
‘‘Development, manufacture and
commercialization of acellular fusion
protein therapy products for the
treatment of cancer in humans, wherein:
1. The fusion protein contains at least
the antigen binding domain of either T
cell receptor (TCR) ‘‘TRAV12–2/
TRBV10/2’’ or ‘‘TRAV4/TRBV5–6 (A, B
or C)’’, as disclosed and claimed in the
Licensed Patent Rights;
2. The cancer expresses mutant KRAS
G12D; and
3. The human(s) express(es) at least
HLA–C*08:02 or HLA–C*05:01.
For the avoidance of doubt,
specifically excluded from this Licensed
Field of Use are cell therapy products
(e.g., T cell or natural killer cell-based)
which have been genetically engineered
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
to express the TCR(s) claimed in the
Licensed Patent Rights.’’
The Intellectual Property is primarily
directed to isolated T cell receptors
(TCRs) reactive to mutated Kirsten rat
sarcoma viral oncogene homolog
(KRAS), within the context of human
leukocyte antigens (HLAs) C*08:02 or
C*05:01. Mutated KRAS, which plays a
well-defined driver role in oncogenesis,
is expressed by a variety of human
cancers, including pancreatic, lung,
endometrial, ovarian and prostate. Due
to its restricted expression in
precancerous and cancerous cells, this
antigen may be targeted on mutant
KRAS-expressing tumors with minimal
normal tissue toxicity.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: May 15, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2024–10970 Filed 5–17–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\20MYN1.SGM
20MYN1
Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Notices
lotter on DSK11XQN23PROD with NOTICES1
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of the Centers of Biomedical
Research Excellence (COBRE) Phase 1.
Date: July 11–12, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Nina Sidorova, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, MSC 6200, Bethesda, Maryland
20892, 301–594–3663, sidorova@
nigms.nih.gov.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of Centers of Biomedical
Research Excellence (COBRE) Phase 1
Applications.
Date: July 18–19, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Jason M. Chan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, MSC 6200, Bethesda, Maryland
20892, 301–594–3663, jason.chan2@nih.gov.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of R13 applications.
Date: July 25, 2024.
Time: 11:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Lee Warren Slice, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3AN12, Bethesda,
Maryland 20892, 301–435–0807, slicelw@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
VerDate Sep<11>2014
19:14 May 17, 2024
Jkt 262001
43861
Dated: May 15, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2024–10989 Filed 5–17–24; 8:45 am]
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; BPN Small Molecule and
Biologic Therapeutic Drug Discovery for
Disorders of the Nervous System.
Date: June 11–12, 2024.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Eric S. Tucker, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH/HHS, NSC, 6001 Executive
Boulevard, Rockville, MD 20852, 301–827–
0799, eric.tucker@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS).
Dated: May 14, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–10968 Filed 5–17–24; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Time-Sensitive
Obesity PAR Review.
Date: June 26, 2024.
Time: 11:30 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIDDK, Democracy II, Suite 7000A, 6707
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7353, 6707 Democracy Blvd.,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: May 15, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–10990 Filed 5–17–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
E:\FR\FM\20MYN1.SGM
20MYN1
]]>Agencies
[Federal Register Volume 89, Number 98 (Monday, May 20, 2024)]
[Notices]
[Pages 43860-43861]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-10989]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of General Medical Sciences; Notice of Closed
Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections
[[Page 43861]]
552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant
applications and the discussions could disclose confidential trade
secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Institute of General Medical
Sciences Special Emphasis Panel; Review of the Centers of Biomedical
Research Excellence (COBRE) Phase 1.
Date: July 11-12, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute of
General Medical Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Nina Sidorova, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute of General Medical
Sciences, National Institutes of Health, 45 Center Drive, MSC 6200,
Bethesda, Maryland 20892, 301-594-3663, [email protected].
Name of Committee: National Institute of General Medical
Sciences Special Emphasis Panel; Review of Centers of Biomedical
Research Excellence (COBRE) Phase 1 Applications.
Date: July 18-19, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute of
General Medical Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Jason M. Chan, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute of General Medical
Sciences, National Institutes of Health, 45 Center Drive, MSC 6200,
Bethesda, Maryland 20892, 301-594-3663, [email protected].
Name of Committee: National Institute of General Medical
Sciences Special Emphasis Panel; Review of R13 applications.
Date: July 25, 2024.
Time: 11:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute of
General Medical Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Lee Warren Slice, Ph.D., Scientific Review
Officer, Office of Scientific Review, National Institute of General
Medical Sciences, National Institutes of Health, 45 Center Drive,
Room 3AN12, Bethesda, Maryland 20892, 301-435-0807,
[email protected].
(Catalogue of Federal Domestic Assistance Program No. 93.859,
Biomedical Research and Research Training, National Institutes of
Health, HHS)
Dated: May 15, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-10989 Filed 5-17-24; 8:45 am]
BILLING CODE 4140-01-P
